Eleven Biotherapeutics Inc (NASDAQ:EBIO)’s conjunctivitis treatment failed late-stage trials, sending shares of the stock plunging over 77 percent. The company was confident it would see good results from the drug, EBI-005. However, it failed to show results in the treatment of ocular itching.
